Company: RAPT Therapeutics
Job title: SVP of Discovery & Pre-Clinical Development
David joined RAPT Therapeutics in 2016 bringing more than 20 years of drug discovery experience. He previously led chemistry efforts at Cleave Biosciences directed towards the discovery and development of first in class agents for the treatments of solid and hematologic malignancies. Previously he directed chemistry efforts at Xenoport, Neurogen and Pfizer.
Leveraging Structure Based Design with Computational Chemistry to Discover Novel USP7 Inhibitors with Enhanced Potency 10:00 am
The deubiquitinase USP7 is a key regulator of oncogenic driver proteins To date, published USP7 inhibitors have suffered from modest potency and/or poor PK Insights gained from structure-based design enhanced with advanced computational chemistry facilitated the discovery of highly potent USP7 inhibitors that show promising activity in anti-tumor modelsRead more
day: Day Two